Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities

Andrew G. King, Kyung Johanson, Carrie L. Frey, Peter L. Demarsh, John R. White, Patrick McDevitt, Dean McNulty, Joanna Balcarek, Zdenka L. Jonak, Pradip K. Bhatnagar, Louis Pelus

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

SK and F 107647, a previously described synthetic immunomodulatory peptide, indirectly stimulates bone marrow progenitor cells and phagocytic cells, and enhances host defense effector mechanisms in bacterial and fungal infection models in vivo. In vitro, SK and F 107647 induces the production of a soluble mediator that augments colony forming cell (CFU-GM) formation in the presence of CSFs. In this paper we purified and sequenced the stromal cell-derived hematopoietic synergistic factors (HSF) secreted from both murine and human cell lines stimulated with SK and F 107647. Murine HSF is an N-terminal 4-aa truncated form of the CXC chemokine, KC, while human HSF was identified as an N-terminal 4-aa truncated form of the CXC chemokine, GROβ. In comparison to their full-length forms, truncated KC and truncated GROβ were 10 million times more potent as synergistic growth stimulants for CFU- GM. Enhanced potency of these novel truncated chemokines relative to their full-length forms was also demonstrated in respiratory burst assays, CD11b Ag expression, and intracellular killing of the opportunistic pathogen, Candida albicans. Administration of truncated KC significantly enhanced survival of mice lethally infected with C. albicans. The results reported herein delineate the biological mechanism of action of SK and F 107647, which functions via the induction of unique specific truncated forms of the chemokines KC and GROβ. To our knowledge, this represents the first example where any form of KC or GROβ were purified from marrow stromal cells. Additionally, this is the first demonstration of in vivo efficacy of a CXC chemokine in an animal infectious fungal disease model.

Original languageEnglish (US)
Pages (from-to)3774-3782
Number of pages9
JournalJournal of Immunology
Volume164
Issue number7
StatePublished - Apr 1 2000
Externally publishedYes

Fingerprint

Chemokines
CXC Chemokines
Granulocyte-Macrophage Progenitor Cells
Mycoses
Stromal Cells
Candida albicans
Respiratory Burst
Phagocytes
Bacterial Infections
Bone Marrow Cells
Communicable Diseases
Stem Cells
Bone Marrow
Cell Line
Peptides
SK&F 107647
Growth

ASJC Scopus subject areas

  • Immunology

Cite this

King, A. G., Johanson, K., Frey, C. L., Demarsh, P. L., White, J. R., McDevitt, P., ... Pelus, L. (2000). Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities. Journal of Immunology, 164(7), 3774-3782.

Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities. / King, Andrew G.; Johanson, Kyung; Frey, Carrie L.; Demarsh, Peter L.; White, John R.; McDevitt, Patrick; McNulty, Dean; Balcarek, Joanna; Jonak, Zdenka L.; Bhatnagar, Pradip K.; Pelus, Louis.

In: Journal of Immunology, Vol. 164, No. 7, 01.04.2000, p. 3774-3782.

Research output: Contribution to journalArticle

King, AG, Johanson, K, Frey, CL, Demarsh, PL, White, JR, McDevitt, P, McNulty, D, Balcarek, J, Jonak, ZL, Bhatnagar, PK & Pelus, L 2000, 'Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities', Journal of Immunology, vol. 164, no. 7, pp. 3774-3782.
King AG, Johanson K, Frey CL, Demarsh PL, White JR, McDevitt P et al. Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities. Journal of Immunology. 2000 Apr 1;164(7):3774-3782.
King, Andrew G. ; Johanson, Kyung ; Frey, Carrie L. ; Demarsh, Peter L. ; White, John R. ; McDevitt, Patrick ; McNulty, Dean ; Balcarek, Joanna ; Jonak, Zdenka L. ; Bhatnagar, Pradip K. ; Pelus, Louis. / Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities. In: Journal of Immunology. 2000 ; Vol. 164, No. 7. pp. 3774-3782.
@article{9fa80b001e6840edad2362261096ab23,
title = "Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities",
abstract = "SK and F 107647, a previously described synthetic immunomodulatory peptide, indirectly stimulates bone marrow progenitor cells and phagocytic cells, and enhances host defense effector mechanisms in bacterial and fungal infection models in vivo. In vitro, SK and F 107647 induces the production of a soluble mediator that augments colony forming cell (CFU-GM) formation in the presence of CSFs. In this paper we purified and sequenced the stromal cell-derived hematopoietic synergistic factors (HSF) secreted from both murine and human cell lines stimulated with SK and F 107647. Murine HSF is an N-terminal 4-aa truncated form of the CXC chemokine, KC, while human HSF was identified as an N-terminal 4-aa truncated form of the CXC chemokine, GROβ. In comparison to their full-length forms, truncated KC and truncated GROβ were 10 million times more potent as synergistic growth stimulants for CFU- GM. Enhanced potency of these novel truncated chemokines relative to their full-length forms was also demonstrated in respiratory burst assays, CD11b Ag expression, and intracellular killing of the opportunistic pathogen, Candida albicans. Administration of truncated KC significantly enhanced survival of mice lethally infected with C. albicans. The results reported herein delineate the biological mechanism of action of SK and F 107647, which functions via the induction of unique specific truncated forms of the chemokines KC and GROβ. To our knowledge, this represents the first example where any form of KC or GROβ were purified from marrow stromal cells. Additionally, this is the first demonstration of in vivo efficacy of a CXC chemokine in an animal infectious fungal disease model.",
author = "King, {Andrew G.} and Kyung Johanson and Frey, {Carrie L.} and Demarsh, {Peter L.} and White, {John R.} and Patrick McDevitt and Dean McNulty and Joanna Balcarek and Jonak, {Zdenka L.} and Bhatnagar, {Pradip K.} and Louis Pelus",
year = "2000",
month = "4",
day = "1",
language = "English (US)",
volume = "164",
pages = "3774--3782",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities

AU - King, Andrew G.

AU - Johanson, Kyung

AU - Frey, Carrie L.

AU - Demarsh, Peter L.

AU - White, John R.

AU - McDevitt, Patrick

AU - McNulty, Dean

AU - Balcarek, Joanna

AU - Jonak, Zdenka L.

AU - Bhatnagar, Pradip K.

AU - Pelus, Louis

PY - 2000/4/1

Y1 - 2000/4/1

N2 - SK and F 107647, a previously described synthetic immunomodulatory peptide, indirectly stimulates bone marrow progenitor cells and phagocytic cells, and enhances host defense effector mechanisms in bacterial and fungal infection models in vivo. In vitro, SK and F 107647 induces the production of a soluble mediator that augments colony forming cell (CFU-GM) formation in the presence of CSFs. In this paper we purified and sequenced the stromal cell-derived hematopoietic synergistic factors (HSF) secreted from both murine and human cell lines stimulated with SK and F 107647. Murine HSF is an N-terminal 4-aa truncated form of the CXC chemokine, KC, while human HSF was identified as an N-terminal 4-aa truncated form of the CXC chemokine, GROβ. In comparison to their full-length forms, truncated KC and truncated GROβ were 10 million times more potent as synergistic growth stimulants for CFU- GM. Enhanced potency of these novel truncated chemokines relative to their full-length forms was also demonstrated in respiratory burst assays, CD11b Ag expression, and intracellular killing of the opportunistic pathogen, Candida albicans. Administration of truncated KC significantly enhanced survival of mice lethally infected with C. albicans. The results reported herein delineate the biological mechanism of action of SK and F 107647, which functions via the induction of unique specific truncated forms of the chemokines KC and GROβ. To our knowledge, this represents the first example where any form of KC or GROβ were purified from marrow stromal cells. Additionally, this is the first demonstration of in vivo efficacy of a CXC chemokine in an animal infectious fungal disease model.

AB - SK and F 107647, a previously described synthetic immunomodulatory peptide, indirectly stimulates bone marrow progenitor cells and phagocytic cells, and enhances host defense effector mechanisms in bacterial and fungal infection models in vivo. In vitro, SK and F 107647 induces the production of a soluble mediator that augments colony forming cell (CFU-GM) formation in the presence of CSFs. In this paper we purified and sequenced the stromal cell-derived hematopoietic synergistic factors (HSF) secreted from both murine and human cell lines stimulated with SK and F 107647. Murine HSF is an N-terminal 4-aa truncated form of the CXC chemokine, KC, while human HSF was identified as an N-terminal 4-aa truncated form of the CXC chemokine, GROβ. In comparison to their full-length forms, truncated KC and truncated GROβ were 10 million times more potent as synergistic growth stimulants for CFU- GM. Enhanced potency of these novel truncated chemokines relative to their full-length forms was also demonstrated in respiratory burst assays, CD11b Ag expression, and intracellular killing of the opportunistic pathogen, Candida albicans. Administration of truncated KC significantly enhanced survival of mice lethally infected with C. albicans. The results reported herein delineate the biological mechanism of action of SK and F 107647, which functions via the induction of unique specific truncated forms of the chemokines KC and GROβ. To our knowledge, this represents the first example where any form of KC or GROβ were purified from marrow stromal cells. Additionally, this is the first demonstration of in vivo efficacy of a CXC chemokine in an animal infectious fungal disease model.

UR - http://www.scopus.com/inward/record.url?scp=0034176111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034176111&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 3774

EP - 3782

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -